Cancer patients have often been excluded from studies of cardiovascular disease (CVD) and patients with significant CVD have been excluded from studies of new cancer therapies. Consequently, the ability to determine the incidence or prevalence of cardiovascular toxic effects of anticancer agents and to determine their optimal management has been limited. This course includes a case study of a patient with breast cancer, with a focus on trastuzumab and anthracycline therapy, as the patient moves from the adjuvant setting to metastatic disease.
- Enhance multidisciplinary awareness of the risks for cardiac toxicity of anthracycline-based chemotherapy followed by taxane chemotherapy combined with trastuzumab in the adjuvant treatment of HER2 positive breast cancer.
- Enhance multidisciplinary awareness of the risks for cardiac toxicity of non-anthracycline-based chemotherapy with trastuzumab in the adjuvant treatment of HER2 positive breast cancer
- Apply knowledge of risk factors for increased cardiac toxicity to guide clinical choice of chemotherapy regimens to combine with trastuzumab in the adjuvant setting.
CME credit is available for this course.
AGCME Competency Addressed: Medical Knowledge
This activity is co-sponsored by the American College of Cardiology Foundation.